Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy. - Wikidata - wikimedia - TriplyDB

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.

http://www.wikidata.org/entity/Q37417396

about

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.

http://www.wikidata.org/entity/Q37417396

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@en

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@nl

type

label

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@en

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@nl

prefLabel

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@en

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@nl

P1433

Q37417396-47DFCA85-4FFE-4525-BDD2-4AE208979C8B

P1476

Q37417396-B9E021A8-BC66-421D-966E-3BAA6D98BC7C

P2093

Q37417396-266FFE4B-A745-4FC3-BE5C-D15F75F3C39D

Q37417396-6F262C9B-AF86-497D-B9B4-09EF26B48451

Q37417396-714E9D4B-42AA-4601-9B7B-4E3F64100EF8

Q37417396-98050F1B-68DD-4C68-8BAE-3909EBEE7119

Q37417396-B5B93628-5D47-4B20-AC78-762A376CE6C0

Q37417396-C61F0073-8594-4BBF-BDE2-91AD246F72B5

P2860

Q37417396-085662B8-D725-4CBE-B18F-A91BCD93DDD4

Q37417396-10AF72E4-C1CC-438A-878F-E260C0BE7109

Q37417396-17D09A2A-1CC1-4504-8D46-2C591BD10743

Q37417396-1B536763-A078-497D-8659-C382A0B7E0F4

Q37417396-1CBDD72F-ECDA-4C13-BA05-7C020CC9E33A

Q37417396-2AA9D4C2-0D50-48A6-97AD-3995A589CE86

Q37417396-3393E814-AF2E-42A3-BD47-E909022342B5

Q37417396-352D2DA3-5D75-4BE4-8A5B-A55BA75E7462

Q37417396-3831CE3B-BDC1-401C-9F74-053C366761C4

Q37417396-3F566DE8-B4FD-4F87-9B66-921058D131E4

P304

Q37417396-CF099BAD-5276-4D38-A458-9C749031EBC9

P31

Q37417396-417CE3AA-22F1-485F-88A2-2D6942E17E18

P356

Q37417396-8254D35E-16AD-47E3-96CC-558C6B54D266

P478

Q37417396-74B18C09-5EC0-497E-8499-42FEF66B96A1

P577

Q37417396-ECF8421B-5B89-486C-8E9A-2CDF7003C423

P5875

Q37417396-DD9C58F7-592A-4A35-817B-99E31DF4915F

P698

Q37417396-E5986C0A-3308-4892-AE05-2978E116DE9F

P932

Q37417396-6A821A9B-3F71-4EAD-B8B8-99DD3E9FE315

P356

P1433

P1476

Improvements in Immune Functio ...... Based Therapy: GRACE Substudy.

@en

P2093

Christos Tsoukas

http://www.w3.org/2001/XMLSchema#string

George Hatzakis

http://www.w3.org/2001/XMLSchema#string

Joseph Mrus

http://www.w3.org/2001/XMLSchema#string

Louise Gilbert

http://www.w3.org/2001/XMLSchema#string

Ron Falcon

http://www.w3.org/2001/XMLSchema#string

Trevor Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir with optimized background therapy for resistant HIV-1 infection

Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.

Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation.

Innate immune recognition and activation during HIV infection.

T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.

Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.

Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.

P304

358294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/358294

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259609028

http://www.w3.org/2001/XMLSchema#string

P698

24396625

http://www.w3.org/2001/XMLSchema#string

P932

3874356

http://www.w3.org/2001/XMLSchema#string